AIM · AIM ImmunoTech Inc. · Documents

Jun 27

Registration statement S-3/A

Registration statement

Jun 20

Current report 8-K Events of Jun 17

Delisting notice or listing transfer, Other events

Jun 12

Current report 8-K Events of May 29

Delisting notice or listing transfer, Charter or bylaw amendment, or fiscal year change, Other events

May 15

Quarterly report 10-Q FY2025 Q1, ended Mar 31

Quarterly report for FY2025 Q1

Revenue $16K ▼ 60.0% Net loss $3.71M Diluted EPS -$0.05

May 1

Current report 8-K Events of Apr 30

Shareholder vote results

Apr 7

Current report 8-K Events of Apr 4

Delisting notice or listing transfer, Other events

Apr 4

Current report 8-K Events of Apr 1

Entered into a material agreement

Apr 2

Proxy statement DEF 14A

Proxy statement

Apr 1

Registration statement S-3

Registration statement

Mar 27

Annual report 10-K FY2024, ended Dec 31

Annual report for FY2024

Revenue $170K ▼ 15.8% Net loss $17.32M Diluted EPS -$0.31

Feb 28

Current report 8-K Events of Feb 26

Other events

Feb 28

Proxy statement PRE 14A

Proxy statement

Feb 26

Current report 8-K Events of Feb 24

Director or officer change, or executive pay, Charter or bylaw amendment, or fiscal year change

Feb 11

Current report 8-K

Other events

Feb 11

Current report 8-K

Other events

Feb 7

Current report 8-K

Other events

Feb 7

Registration statement S-1/A

Registration statement

Feb 5

Current report 8-K

Other events

Feb 3

Registration statement S-1/A

Registration statement

Jan 23

Registration statement S-1

Registration statement

Dec 23

Current report 8-K Events of Dec 19

Director or officer change, or executive pay

Dec 20

Current report 8-K Events of Dec 17

Shareholder vote results

Dec 17

Current report 8-K Events of Dec 11

Delisting notice or listing transfer, Other events

Dec 17

Proxy statement DEFA14A

Proxy statement

Dec 16

Proxy statement DEFA14A

Proxy statement

Dec 12

Proxy statement DEFA14A

Proxy statement

Dec 10

Proxy statement DEFA14A

Proxy statement

Dec 9

Proxy statement DEFA14A

Proxy statement

Dec 6

Proxy statement DEFA14A

Proxy statement

Dec 5

Proxy statement DEFA14A

Proxy statement

Dec 4

Proxy statement DEFA14A

Proxy statement

Dec 2

Proxy statement DEFA14A

Proxy statement

Nov 27

Current report 8-K Events of Nov 25

Regulation FD disclosure, Other events

Nov 27

Proxy statement DEFA14A

Proxy statement

Nov 27

Proxy statement DEFA14A

Proxy statement

Nov 25

Proxy statement DEFA14A

Proxy statement

Nov 22

Proxy statement DEFA14A

Proxy statement

Nov 15

Proxy statement DEFA14A

Proxy statement

Nov 15

Registration statement S-1

Registration statement

Nov 14

Quarterly report 10-Q FY2024 Q3, ended Sep 30

Quarterly report for FY2024 Q3

Revenue $35K ▼ 23.9% Net loss $3.7M Diluted EPS -$0.06

Nov 8

Proxy statement DEFA14A

Proxy statement

Nov 4

Proxy statement DEFA14A

Proxy statement

Oct 1

Current report 8-K Events of Sep 30

Entered into a material agreement, Unregistered sale of equity, Other events

Sep 12

Current report 8-K Events of Sep 11

Unregistered sale of equity, Director or officer change, or executive pay

Aug 14

Quarterly report 10-Q FY2024 Q2, ended Jun 30

Quarterly report for FY2024 Q2

Revenue $50K ▲ 19.0% Net loss $1.84M Diluted EPS -$0.03

Aug 1

Current report 8-K Events of Jul 31

Charter or bylaw amendment, or fiscal year change

Jul 15

Current report 8-K Events of Jul 12

Other events

Jul 11

Registration statement S-1

Registration statement

Jun 3

Current report 8-K Events of May 31

Entered into a material agreement, Unregistered sale of equity, Other events

May 15

Quarterly report 10-Q FY2024 Q1, ended Mar 31

Quarterly report for FY2024 Q1

Revenue $40K ▼ 18.4% Net loss $5.82M Diluted EPS -$0.12